Clinical Trials Logo

Clinical Trial Summary

Coronary allograft vasculopathy represents one of the major limiting factors of long-term survival in heart transplant recipients. While extensively researched, the underlying mechanisms of coronary allograft vasculopathy (CAV) after heart transplantation remain incompletely understood. As CD34+ cells represent one of the key determinants of coronary vascular homeostasis we investigated the potential association between CAV and CD34+ cell count in heart transplant recipients.


Clinical Trial Description

In a single-center prospective pilot cohort study, we aim to enroll 55 adult heart transplant recipients. All patients will undergo coronary CT angiography and the presence of CAV will be defined in accordance with the ISHLT criteria. At the time of CT angiography, patient will undergo detailed clinical evaluation, cardiac echo and we will also collect blood samples, perform extensive biochemical analysis and measure CD34+ cell count in peripheral venous blood using Beckman-Coulter Navios EX flow cytometry with standard antibodies according to ISAGE protocol. Biomarkers of angiogenesis will be evaluated using Luminex assay kit. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05485467
Study type Observational
Source University Medical Centre Ljubljana
Contact
Status Completed
Phase
Start date June 1, 2022
Completion date August 31, 2022

See also
  Status Clinical Trial Phase
Completed NCT05038943 - Evaluation of Safety and Effectiveness of The SherpaPak in Donation After Circulatory Death Heart Transplantation N/A
Recruiting NCT06140810 - Impact of Atelectasis on RVEDP Following Orthotropic Heart Transplantation
Recruiting NCT06428097 - Levothyroxine Supplementation for Heart Transplant Recipients Phase 1
Recruiting NCT05321706 - DAPAgliflozin for Renal Protection in Heart Transplant Recipients Phase 3
Recruiting NCT06338306 - Tacrolimus and Personalized Therapy to Prevent Acute Rejection Episodes
Completed NCT04626284 - Safety and Effectiveness of NRP for DCD Heart Transplantation N/A
Recruiting NCT04180085 - Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR) Phase 2
Completed NCT03671408 - Levels of High-Sensitivity C-Reactive Protein in Heart Transplant Patients